Controlled Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self
受控时空递送 miRNA Anatgomir 以促进血管自身
基本信息
- 批准号:8138278
- 负责人:
- 金额:$ 20.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-19 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:Angiogenic ProteinsBiochemicalBiologyBiomedical EngineeringBlood VesselsBurn injuryCartilageCell Culture TechniquesCell SurvivalCellsCholesterolCollagenCytoplasmDevelopmentDiabetes MellitusDiseaseEffectivenessEncapsulatedEndothelial CellsExtravasationFeedbackFibronectinsFlow CytometryFluorescence MicroscopyFunctional RNAGelGenerationsGenesHistocompatibility TestingHumanImmunodeficient MouseImmunologyImplantIn VitroIncubatedLabelLeadLifeLiver FailureMessenger RNAMicroRNAsMicroscopyMicrospheresMonocyte Chemoattractant Protein-1Pathway interactionsPerfusionPericytesPolymersProcessProteinsPublic HealthRNA SequencesRegenerative MedicineResearch PersonnelSCID MiceSkinSmooth Muscle MyocytesStructureSuspension substanceSuspensionsSystemTechniquesTechnologyTestingTherapeuticTissue EngineeringTissuesToxic effectTranslationsVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsVascularizationWorkabstractingangiogenesisbiodegradable polymerclinical practicecontrolled releasedesignimplantationimprovedin vitro Assayin vivonanoparticlenew technologyself assemblyspatiotemporaluptake
项目摘要
DESCRIPTION (provided by applicant):
Previous work has demonstrated that well differentiated human endothelial cells (ECs) will self assemble into vascular conduits in protein gels both in vitro and in vivo after implantation into immunodeficient mouse hosts. Vessel maturation in grafts containing only EC requires recruitment of host mural cells, such as vascular smooth muscle cells or pericytes (PCs). The maturation of vessels is accelerated and enhanced when ECs are co-implanted with human PCs. Vessel self assembly can also be enhanced by sustained delivery of pro- angiogenic proteins that act on ECs or PCs, especially when an EC-directed agent, vascular endothelial growth factor (VEGF), is combined with a PC-directed agent, monocyte chemotactic protein -1 (MCP-1). However, vessel self-assembly and maturation still appears too slow to optimize parenchymal cell survival, requiring at least 10 days. The actions of pro-angiogenic proteins may be augmented or limited by positive and negative feedback loops, respectively, within the target cells that involve microRNAs (miRNAs). miRNAs are short, non-coding RNAs that regulate a variety of development processes by reducing specific mRNA half lives or translation. A single miRNA can reduce the expression of multiple genes often in the same pathway. The effects of miRNAs can be inhibited by complementary short RNA sequences referred to as antagomirs. Antagomirs act in a cell-specific manner when the miRNA is expressed in a cell specific manner. This project tests the hypothesis that controlled delivery of an antagomir can enhance the therapeutic benefits of angiogenic proteins such as VEGF in vascular self-assembly. This hypothesis will be tested through two specific aims. In Aim 1, polymer nanoparticles (NP) will be used to find the optimal approaches for providing spatial and temporal control over miRNA and antagomir delivery to the cytoplasm of ECs in 3D culture. In Aim 2, these NP delivery systems will be tested for their ability to control the spatial and temporal delivery of antagomirs to miR-17/20-which is known to augment the effects of VEGF-to 3D cell cultures produced by suspending ECs and PCs in gels of collagen and fibronectin. (End of Abstract)
描述(由申请人提供):
先前的工作表明,分化良好的人内皮细胞(EC)在植入免疫缺陷小鼠宿主后,无论在体外还是在体内,都会在蛋白质凝胶中自组装成血管导管。仅含有 EC 的移植物中的血管成熟需要募集宿主壁细胞,例如血管平滑肌细胞或周细胞 (PC)。当 EC 与人类 PC 共同植入时,血管的成熟会加速和增强。血管自组装也可以通过持续递送作用于 EC 或 PC 的促血管生成蛋白来增强,特别是当 EC 导向剂、血管内皮生长因子 (VEGF) 与 PC 导向剂、单核细胞趋化蛋白相结合时-1(MCP-1)。然而,血管自组装和成熟仍然显得太慢,无法优化实质细胞的存活,至少需要 10 天。在涉及 microRNA (miRNA) 的靶细胞内,促血管生成蛋白的作用可能分别受到正反馈环和负反馈环的增强或限制。 miRNA 是短的非编码 RNA,通过缩短特定 mRNA 半衰期或翻译来调节多种发育过程。单个 miRNA 可以降低同一途径中多个基因的表达。 miRNA 的作用可以被称为 antagomir 的互补短 RNA 序列抑制。当 miRNA 以细胞特异性方式表达时,Antagomirs 以细胞特异性方式发挥作用。该项目测试了以下假设:antagomir 的受控递送可以增强血管生成蛋白(例如 VEGF)在血管自组装中的治疗效果。这一假设将通过两个具体目标进行检验。在目标 1 中,聚合物纳米颗粒 (NP) 将用于寻找最佳方法,以在 3D 培养中对 miRNA 和 antagomir 递送至 EC 细胞质提供空间和时间控制。在目标 2 中,将测试这些 NP 递送系统控制 antagomir 向 miR-17/20 的空间和时间递送的能力,已知 miR-17/20 可以增强 VEGF 对悬浮 EC 和 PC 产生的 3D 细胞培养物的影响胶原蛋白和纤连蛋白凝胶中。 (摘要完)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JORDAN S POBER其他文献
JORDAN S POBER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JORDAN S POBER', 18)}}的其他基金
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium
针对人同种异体移植物内皮的体外纳米颗粒药物输送
- 批准号:
10783379 - 财政年份:2023
- 资助金额:
$ 20.69万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10194232 - 财政年份:2021
- 资助金额:
$ 20.69万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10353416 - 财政年份:2021
- 资助金额:
$ 20.69万 - 项目类别:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
通过内皮细胞移植优化治疗性血运重建
- 批准号:
9516109 - 财政年份:2017
- 资助金额:
$ 20.69万 - 项目类别:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
针对人肾同种异体移植物内皮的体外纳米颗粒药物输送
- 批准号:
10155842 - 财政年份:2017
- 资助金额:
$ 20.69万 - 项目类别:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
针对人肾同种异体移植物内皮的体外纳米颗粒药物输送
- 批准号:
10197784 - 财政年份:2017
- 资助金额:
$ 20.69万 - 项目类别:
Targeting Nanoparticles for Drug Delivery to Renal Graft Endothelium during Ex Vivo Normothermic Perfusion
体外常温灌注期间靶向纳米颗粒将药物递送至肾移植物内皮
- 批准号:
9164300 - 财政年份:2016
- 资助金额:
$ 20.69万 - 项目类别:
Bioengineered siRNA/Nanoparticles to Prevent Human Transplant Rejection
生物工程 siRNA/纳米颗粒可防止人体移植排斥
- 批准号:
8693080 - 财政年份:2013
- 资助金额:
$ 20.69万 - 项目类别:
Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self-Assembly
miRNA Anatgomir 的时空传递促进血管自组装
- 批准号:
8322816 - 财政年份:2011
- 资助金额:
$ 20.69万 - 项目类别:
相似国自然基金
军团菌真核样丝/苏氨酸激酶效应蛋白的生化及生物学功能研究
- 批准号:32170182
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
壬基酚聚氧乙烯醚(NPnEO)废水生化处理过程中内分泌干扰毒性变化规律及微生物学机制
- 批准号:51908276
- 批准年份:2019
- 资助金额:26.0 万元
- 项目类别:青年科学基金项目
嗜肺军团菌OTU家族效应蛋白生化及生物学功能研究
- 批准号:31770149
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
洋底深部真菌利用褐煤产甲烷的生化过程及代谢机理
- 批准号:41773083
- 批准年份:2017
- 资助金额:69.0 万元
- 项目类别:面上项目
帕金森病合并轻度认知障碍不同亚型的脑影像和血液生化研究
- 批准号:31700960
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
3D in vitro model of skeletal muscle development using stiffening silk biomaterials
使用硬化丝生物材料的骨骼肌发育的 3D 体外模型
- 批准号:
10629500 - 财政年份:2022
- 资助金额:
$ 20.69万 - 项目类别:
3D in vitro model of skeletal muscle development using stiffening silk biomaterials
使用硬化丝生物材料的骨骼肌发育的 3D 体外模型
- 批准号:
10629500 - 财政年份:2022
- 资助金额:
$ 20.69万 - 项目类别:
Targeting epithelial membrane protein 2 (EMP2) in retinopathy of prematurity
靶向上皮膜蛋白 2 (EMP2) 治疗早产儿视网膜病变
- 批准号:
10404080 - 财政年份:2021
- 资助金额:
$ 20.69万 - 项目类别:
Targeting epithelial membrane protein 2 (EMP2) in retinopathy of prematurity
靶向上皮膜蛋白 2 (EMP2) 治疗早产儿视网膜病变
- 批准号:
10624426 - 财政年份:2021
- 资助金额:
$ 20.69万 - 项目类别:
Targeting epithelial membrane protein 2 (EMP2) in retinopathy of prematurity
靶向上皮膜蛋白 2 (EMP2) 治疗早产儿视网膜病变
- 批准号:
10183025 - 财政年份:2021
- 资助金额:
$ 20.69万 - 项目类别: